RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 173 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.4%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,432 | -57.8% | 59,231 | -55.5% | 0.00% | -50.0% |
| Q1 2024 | $5,768 | -51.2% | 133,136 | -48.2% | 0.00% | -50.0% |
| Q4 2023 | $11,815 | +113.6% | 257,015 | +6.5% | 0.00% | +33.3% |
| Q3 2023 | $5,531 | +157.6% | 241,261 | +85.3% | 0.00% | +200.0% |
| Q2 2023 | $2,147 | +38.2% | 130,228 | +49.5% | 0.00% | 0.0% |
| Q1 2023 | $1,554 | -70.8% | 87,118 | -52.3% | 0.00% | -50.0% |
| Q4 2022 | $5,317 | -99.9% | 182,599 | +11.1% | 0.00% | -50.0% |
| Q3 2022 | $4,027,000 | +10225.6% | 164,353 | +1669.1% | 0.00% | – |
| Q2 2022 | $39,000 | -84.1% | 9,290 | -56.2% | 0.00% | – |
| Q1 2022 | $245,000 | -77.0% | 21,199 | -80.2% | 0.00% | – |
| Q4 2021 | $1,066,000 | +131.2% | 106,938 | +203.0% | 0.00% | – |
| Q3 2021 | $461,000 | +27.0% | 35,294 | +90.9% | 0.00% | – |
| Q2 2021 | $363,000 | -77.0% | 18,488 | -75.1% | 0.00% | -100.0% |
| Q1 2021 | $1,581,000 | +53.0% | 74,283 | +113.7% | 0.00% | 0.0% |
| Q4 2020 | $1,033,000 | -50.9% | 34,756 | -64.2% | 0.00% | 0.0% |
| Q3 2020 | $2,105,000 | -7.3% | 97,125 | -4.6% | 0.00% | -50.0% |
| Q2 2020 | $2,270,000 | +59.1% | 101,851 | +8.7% | 0.00% | +100.0% |
| Q1 2020 | $1,427,000 | -51.4% | 93,724 | -26.7% | 0.00% | -50.0% |
| Q4 2019 | $2,935,000 | +871.9% | 127,847 | +815.4% | 0.00% | – |
| Q3 2019 | $302,000 | -25.6% | 13,966 | -24.5% | 0.00% | – |
| Q2 2019 | $406,000 | -24.3% | 18,487 | -5.3% | 0.00% | – |
| Q1 2019 | $536,000 | +495.6% | 19,523 | +487.0% | 0.00% | – |
| Q4 2018 | $90,000 | -53.4% | 3,326 | -49.8% | 0.00% | – |
| Q3 2018 | $193,000 | +370.7% | 6,627 | +400.2% | 0.00% | – |
| Q2 2018 | $41,000 | -51.2% | 1,325 | -68.2% | 0.00% | – |
| Q1 2018 | $84,000 | +121.1% | 4,168 | +219.1% | 0.00% | – |
| Q4 2017 | $38,000 | – | 1,306 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 735,000 | $13,112,400 | 3.93% |
| NEA Management Company, LLC | 2,909,956 | $51,913,615 | 3.59% |
| Frazier Life Sciences Management, L.P. | 2,164,739 | $38,618,944 | 2.80% |
| RA Capital Management | 5,516,067 | $98,406,635 | 2.23% |
| Samsara BioCapital, LLC | 345,293 | $6,160,027 | 1.27% |
| Rock Springs Capital Management LP | 1,597,123 | $28,492,674 | 0.68% |
| Baker Brothers Advisors | 6,498,267 | $115,929,083 | 0.63% |
| HighVista Strategies LLC | 35,478 | $632,928 | 0.52% |
| Nan Fung Group Holdings Ltd | 32,520 | $580,157 | 0.40% |
| GREAT POINT PARTNERS LLC | 97,544 | $1,740,185 | 0.34% |